Skip to main navigation Skip to search Skip to main content

Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during I-131-metaiodobenzylguanidine treatment in children with neuroblastoma

  • S. C. Clement*
  • , R. R. van Rijn
  • , B. L. E. van Eck-Smit
  • , A. S. P. van Trotsenburg
  • , H. N. Caron
  • , G. A. M. Tytgat
  • , H. M. van Santen
  • *Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Purpose Treatment with I-131-MIBG is associated with significant thyroid damage. This study was undertaken to investigate the long-term efficacy of current thyroid prophylaxis, to explore the relationship between thyroid dysfunction and thyroid volume after exposure to I-131-MIBG and to evaluate the possible negative effects of I-131-on the parathyroid glands.

Methods Of 81 long-term surviving patients with neuroblastoma treated with I-131-MIBG during the period 1999-2012, 24 were finally evaluated. Patients received thyroxine (T4), methimazole and potassium iodide as thyroid protection. In all patients (para) thyroid function was evaluated and ultrasound investigation of the (para) thyroid gland(s) was performed. Thyroid dysfunction was defined as a plasma thyrotropin concentration >5.0 mU/L (thyrotropin elevation, TE) or as the use of T4 at the time of follow-up. Hyperparathyroidism was defined as a serum calcium concentration above the age-related reference range in combination with an inappropriately high parathyroid hormone level.

Results At a median follow-up of 9.0 years after I-131-MIBG treatment, thyroid disorders were seen in 12 patients (50 %; 9 with TE, 5 with a thyroid nodule and 1 patient was subsequently diagnosed with differentiated thyroid carcinoma). No significant risk factors for the occurrence of thyroid damage could be identified. In 14 of 21 patients (67 %) in whom thyroid volume could be determined, the volume was considered small (

Conclusion Thyroid protection during treatment with I-131-MIBG needs attention and must be further improved, as thyroid disorders are still frequently seen despite current thyroid prophylaxis. Reduced thyroid volume in neuroblastoma survivors may be related to previous I-131-MIBG therapy or current T4 treatment. No deleterious effects of I-131-MIBG on the parathyroid glands could be found.

Original languageEnglish
Pages (from-to)706-715
Number of pages10
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume42
Issue number5
DOIs
Publication statusPublished - Apr 2015

Keywords

  • I-131-Metaiodobenzylguanidine
  • Neuroblastoma
  • Thyroid dysfunction
  • Thyroid carcinoma
  • Thyroid volume
  • Radiation damage
  • CHILDHOOD-CANCER SURVIVOR
  • I-131-MIBG THERAPY
  • POTASSIUM-IODIDE
  • RADIOLABELED METAIODOBENZYLGUANIDINE
  • PRIMARY HYPOTHYROIDISM
  • RADIOTHERAPY
  • RISK
  • DYSFUNCTION
  • CARCINOMA
  • UPDATE

Fingerprint

Dive into the research topics of 'Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during I-131-metaiodobenzylguanidine treatment in children with neuroblastoma'. Together they form a unique fingerprint.

Cite this